{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["34"],"submitter":["Lin DI"],"pubmed_abstract":["Mesonephric carcinoma is a rare cancer that most often arises within the cervix, and less frequently, in the ovary and endometrium. A retrospective search of our CLIA-certified and CAP-accredited reference molecular laboratory database (Foundation Medicine, Inc.) identified 20 mesonephric or mesonephric-like, cervical (n = 10), endometrial (n = 5), ovarian (n = 4) or peri-bladder (n = 1) carcinomas that had undergone comprehensive genomic profiling via next generation sequencing. Activating <i>KRAS</i> mutations were present in 90%, 18 of 20 cases, including G12V (n = 7), G12D (n = 6), G12A (n = 3) and G12C (n = 2). Other recurrent alterations were identified in <i>ARID1A</i> (25%), <i>PIK3CA</i> (20%), <i>CTNNB1</i> (15%), <i>TP53</i> (10%), <i>MLL2</i> (10%) and <i>CDKN2A</i> (10%). One "],"journal":["Gynecologic oncology reports"],"pagination":["100652"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7529833"],"repository":["biostudies-literature"],"pubmed_title":["Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin."],"pmcid":["PMC7529833"],"pubmed_authors":["Killian JK","Shah N","Hemmerich A","Severson EA","Huang RSP","Elvin JA","Haberberger J","Tse JY","Edgerly C","Ramkissoon SH","Lin DI","Vergilio JA","Ross JS"],"additional_accession":[]},"is_claimable":false,"name":"Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin.","description":"Mesonephric carcinoma is a rare cancer that most often arises within the cervix, and less frequently, in the ovary and endometrium. A retrospective search of our CLIA-certified and CAP-accredited reference molecular laboratory database (Foundation Medicine, Inc.) identified 20 mesonephric or mesonephric-like, cervical (n = 10), endometrial (n = 5), ovarian (n = 4) or peri-bladder (n = 1) carcinomas that had undergone comprehensive genomic profiling via next generation sequencing. Activating <i>KRAS</i> mutations were present in 90%, 18 of 20 cases, including G12V (n = 7), G12D (n = 6), G12A (n = 3) and G12C (n = 2). Other recurrent alterations were identified in <i>ARID1A</i> (25%), <i>PIK3CA</i> (20%), <i>CTNNB1</i> (15%), <i>TP53</i> (10%), <i>MLL2</i> (10%) and <i>CDKN2A</i> (10%). One ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-04-18T19:38:24.412Z","creation":"2020-11-07T09:59:44Z"},"accession":"S-EPMC7529833","cross_references":{"pubmed":["33024807"],"doi":["10.1016/j.gore.2020.100652"]}}